Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Target Price at $37.17

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $39.8333.

TYRA has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. Piper Sandler raised their target price on Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, January 23rd. William Blair assumed coverage on Tyra Biosciences in a report on Tuesday. They set an “outperform” rating on the stock. Finally, Wedbush upped their price target on Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a research report on Friday.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Robert J. More sold 246,871 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $20.25, for a total value of $4,999,137.75. Following the transaction, the director owned 3,833,425 shares in the company, valued at $77,626,856.25. This represents a 6.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Tyra Biosciences during the 4th quarter valued at $51,000. Chung Wu Investment Group LLC acquired a new position in shares of Tyra Biosciences in the fourth quarter worth $53,000. Federated Hermes Inc. raised its holdings in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after acquiring an additional 1,841 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Tyra Biosciences during the fourth quarter valued at $220,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Price Performance

Shares of TYRA opened at $27.99 on Wednesday. The company has a 50-day moving average of $27.66 and a two-hundred day moving average of $18.86. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -14.97 and a beta of 1.07. Tyra Biosciences has a one year low of $6.42 and a one year high of $33.99.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.